2-(4-bromophenyl)-2-oxoethyl (R)-3-(hexyloxy)tetradecanoate | 1092962-69-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-bromophenyl)-2-oxoethyl (R)-3-(hexyloxy)tetradecanoate
• CAS: 1092962-69-0
• 化学式: C₂₈H₄₅BrO₄
• 分子量: 525.567
• InChiKey: QGXSMWDBAPWOIQ-AREMUKBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.45
• 重原子数：
  33.0
• 可旋转键数：
  21.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2-(4-bromophenyl)-2-oxoethyl (R)-3-(hexyloxy)tetradecanoate 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以100%的产率得到(3R)-3-hexoxytetradecanoic acid
  参考文献：
  名称：

  The ‘Ethereal’ nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics

  摘要：

  To overcome the chemical and metabolic instability of the secondary fatty acyl residues in the AGP class of lipid A mimetics, the secondary ether lipid analogs of the potent TLR4 agonist CRX-527 (2) and TLR4 antagonist CRX-526 (3) were synthesized and evaluated along with their ester counterparts for agonist/antagonist activity in both in vitro and in vivo models. Like CRX-527, the secondary ether lipid 4 showed potent agonist activity in both murine and human models. Ether lipid 5, on the other hand, showed potent TLR4 antagonist activity similar to CRX-526 in human cell assays, but did not display any antagonist activity in murine models and, in fact, was weakly agonistic. Glycolipids 2, 4, and 5 were synthesized via a new highly convergent method utilizing a common advanced intermediate strategy. A new method for preparing (R)-3-alkyloxytetradecanoic acids, a key component of ether lipids 4 and 5, is also described. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.060
• 作为产物：
  描述：

  2-(4-bromophenyl)-2-oxoethyl (R)-3-((tert-butyldimethylsilyl)oxy)tetradecanoate 、 正己醛 在 三乙基硅烷 、 bismuth(III) bromide 作用下， 以 乙腈 为溶剂， 反应 0.33h， 以82%的产率得到2-(4-bromophenyl)-2-oxoethyl (R)-3-(hexyloxy)tetradecanoate
  参考文献：
  名称：

  The ‘Ethereal’ nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics

  摘要：

  To overcome the chemical and metabolic instability of the secondary fatty acyl residues in the AGP class of lipid A mimetics, the secondary ether lipid analogs of the potent TLR4 agonist CRX-527 (2) and TLR4 antagonist CRX-526 (3) were synthesized and evaluated along with their ester counterparts for agonist/antagonist activity in both in vitro and in vivo models. Like CRX-527, the secondary ether lipid 4 showed potent agonist activity in both murine and human models. Ether lipid 5, on the other hand, showed potent TLR4 antagonist activity similar to CRX-526 in human cell assays, but did not display any antagonist activity in murine models and, in fact, was weakly agonistic. Glycolipids 2, 4, and 5 were synthesized via a new highly convergent method utilizing a common advanced intermediate strategy. A new method for preparing (R)-3-alkyloxytetradecanoic acids, a key component of ether lipids 4 and 5, is also described. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.060